Delivery Order SPE2DR25D9353-SPE2DR26FQWP8
Award Date 2/9/26
Potential Completion Date 2/10/26
Potential Value $30K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 12, 2026, with a ceiling value of $6,142.92, for the supply of Fasenra pen 30 mg/ml under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products and medical consumables to support Department of Defense healthcare operations globally....
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 10, 2026, with a ceiling value of $16,149.52, for supply of Fasenra 30 mg/mL under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a DLA-administered indefinite delivery contract vehicle supporting pharmaceutical supply to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 6, 2026, for $73,715.04 (ceiling value) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for supply of FASENRA PEN 30 MG/ML. PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceuticals, biologics, and medical consumables to support Department of Defense military healthcare facilities worldwide....
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 5, 2026, for $2,493.75 to supply Fasenra (reslizumab) 30 mg/mL under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). DMS Pharmaceutical Group Inc. is a woman-owned small business. The order is issued under the PPV-G GEN V, a Defense Logistics Agency single-award indefinite delivery contract with a $499.999 billion ceiling and ultimate completion date of December 31,...
- The Defense Logistics Agency (DLA) awarded a $39,900 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Fasenra 30 mg/mL syringes. The award, issued on December 17, 2025, with a completion date of December 18, 2025, represents a firm fixed-price delivery order with no set-aside designation. This contract leverages DMS Pharmaceutical Group's position as a regional prime vendor under the DLA's Pharmaceutical...
- The Defense Logistics Agency issued a $6,142.92 delivery order to DMS Pharmaceutical Group Inc. on February 11, 2026, for FASENRA PEN 30 MG/ML under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler. The order is issued under the company's single-award Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency, which carries a $499.999 billion ceiling and runs through...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 9, 2026, for FASENRA PEN 30 MG/ML with a ceiling value of $6,142.92, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency program authorizing firm fixed-price delivery orders for pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense military...
- The Defense Logistics Agency issued a $18,428.76 delivery order to DMS Pharmaceutical Group Inc. on February 10, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for Fasenra (benralizumab) 30 mg/mL. PPV-G GEN V is a Defense Logistics Agency pharmaceutical prime vendor program authorizing firm fixed-price delivery orders for branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare operations...
- The Defense Logistics Agency awarded a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fasenra Pen 30 mg/mL. The award was issued on January 29, 2026, with an ultimate completion date of January 30, 2026, under a firm fixed-price contract structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 12, 2026, with a ceiling value of $6,142.92, for FASENRA PEN 30 MG/ML under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products, biologics, and medical consumables to support Department of Defense healthcare operations worldwide. DMS...